Myocardial Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis: Specialized Protocols for Better Diagnosis.
In Chang HwangJi In BangYeonyee Elizabeth YoonWon Woo LeePublished in: Journal of cardiovascular imaging (2020)
Sarcoidosis is a multisystemic granulomatous disease of unknown etiology with various clinical presentations depending on the organs involved. Since cardiac sarcoidosis (CS) portends a higher risk of morbidity and mortality, early diagnosis and aggressive medical treatment are essential to improve the prognosis. 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) has emerged as an important tool with practical advantages in assessing disease activity and monitoring the treatment response in patients with CS. While it has high sensitivity, it also has great variability in specificity, probably due to normal physiologic myocardial FDG uptake, which interferes with the evaluation and follow-up of CS using FDG-PET. This review details the technical aspects of FDG-PET imaging for evaluating and diagnosing CS, assessing disease activity, and monitoring therapeutic response.
Keyphrases
- positron emission tomography
- disease activity
- pet imaging
- computed tomography
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- left ventricular
- ankylosing spondylitis
- pet ct
- juvenile idiopathic arthritis
- heart failure
- palliative care
- atrial fibrillation
- idiopathic pulmonary fibrosis